Literature DB >> 9163661

Parapneumonic effusion and empyema.

H Hamm1, R W Light.   

Abstract

Parapneumonic effusions account for about one third of all pleural effusions. Approximately 40% of patients with pneumonia develop a concomitant effusion, which is associated with an increased morbidity and mortality. In order to select the most appropriate therapy for the individual patient, the effusion should be categorized as being in the exudative, fibropurulent, or organizational stage, and all necessary information should be compiled to decide whether the effusion is likely to take an uncomplicated or a complicated course. There is a considerable variation in the aggressiveness and course of parapneumonic effusions, and, therefore, the spectrum of the appropriate therapy may vary from a conservative approach in uncomplicated effusions to aggressive surgical intervention in advanced multiloculated empyemas. This review discusses current diagnostic and therapeutic options and offers guidelines for treating the various stages of parapneumonic effusions and empyemas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163661     DOI: 10.1183/09031936.97.10051150

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  32 in total

1.  BTS guidelines for the investigation of a unilateral pleural effusion in adults.

Authors:  N A Maskell; R J A Butland
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

3.  BTS guidelines for the management of pleural infection in children.

Authors:  I M Balfour-Lynn; E Abrahamson; G Cohen; J Hartley; S King; D Parikh; D Spencer; A H Thomson; D Urquhart
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

4.  The role of pleural fluid-serum gradient of tumor necrosis factor-alpha concentration in discrimination between complicated and uncomplicated parapneumonic effusion.

Authors:  M Odeh; B Makhoul; E Sabo; I Srugo; A Oliven
Journal:  Lung       Date:  2005 Jan-Feb       Impact factor: 2.584

5.  Thoracotomy versus video-assisted thoracoscopic surgery (VATS) in stage III empyema-an analysis of 217 consecutive patients.

Authors:  Martin Reichert; Bernd Pösentrup; Andreas Hecker; Emmanuel Schneck; Jörn Pons-Kühnemann; Florian Augustin; Winfried Padberg; Dietmar Öfner; Johannes Bodner
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

6.  Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion.

Authors:  Kalliopi Chatzika; Katerina Manika; Paschalina Kontou; Georgia Pitsiou; Despina Papakosta; Konstantinos Zarogoulidis; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

Review 7.  Clinical practice: treatment of childhood empyema.

Authors:  Marijke Proesmans; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2009-02-24       Impact factor: 3.183

Review 8.  Pneumonia and empyema: causal, casual or unknown.

Authors:  Lindsay McCauley; Nathan Dean
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

9.  Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.

Authors:  Maria Saroglou; Stavros Tryfon; Georgios Ismailos; Ioannis Liapakis; Manolis Tzatzarakis; Aristidis Tsatsakis; Apostolos Papalois; Demosthenes Bouros
Journal:  J Inflamm (Lond)       Date:  2010-05-18       Impact factor: 4.981

10.  Management of thoracic empyema in childhood: does the pleural thickening matter?

Authors:  B Satish; M Bunker; P Seddon
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.